Corticosteroid and central serous chorioretinopathy
LuEsther T. Mertz Retinal Research Department, Manhattan Eye, Ear and Throat Hospital, New York, New York 10021, USA. Ophthalmology
(Impact Factor: 6.14).
10/2002; 109(10):1834-7. DOI: 10.1016/S0161-6420(02)01117-X
The purpose of this study is to investigate the relationship between corticosteroid use and central serous chorioretinopathy (CSC).
A prospective, case-controlled study.
A consecutive series of patients with acute manifestations of CSC and a control group matched for age, race, and gender were recruited between January 2000 and July 2000.
A detailed clinical history was taken, and fundus examination with slit-lamp biomicroscopy was performed on all patients. Fluorescein angiography was obtained on the study patients.
A total of 50 patients was recruited. Twenty-six patients (52%) had a history of exogenous steroid use, including oral, intravenous, intranasal, and intraarticular administration. Two additional patients had a history of endogenous hypercortisolism (Cushing's syndrome). In a matched control group, eight patients (18%) had a history of steroid use. The difference in corticosteroid exposure between study patients and controls was statistically significant (P < 0.0001).
History of corticosteroid use or Cushing's syndrome.
This study is consistent with previous reports associating steroid use with CSC. It identifies corticosteroids as a significant risk factor for the development of acute, exudative macular manifestation and implicates hypercortisolism as a factor in the pathogenesis of this disorder. Several forms of corticosteroid administration were observed to be a risk factor for CSC. Accordingly, susceptible patients in need of corticosteroids should be advised of the risk of developing acute manifestations of CSC.
Available from: PubMed Central
- "Adrenocortical hormone plays an important role in ICSCR. Elevation of serum glucocorticosteroid is associated with an increased risk of ICSCR.21 In this study, we used omeprazole (20 mg), clarithromycin (500 mg), and amoxicillin (1,000 mg) to eradicate H. pylori. "
[Show abstract] [Hide abstract]
ABSTRACT: To evaluate the effect of Helicobacter pylori (H. pylori) eradication on the remission of acute idiopathic central serous chorioretinopathy (ICSCR).
A prospective, randomized, placebo-controlled study of 53 participants.
Twenty-seven acute ICSCR patients tested positive for H. pylori were given an eradication H. pylori therapy, and another 26 patients with the same diagnosis received matching placebo medication. All participants were tested for the following items: (1) disappearance rate of subretinal fluid (SRF); (2) best-corrected visual acuity (BCVA); and (3) central retinal sensitivity at baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks after treatment. The difference between the two groups was analyzed by PASW statistics version 18.0.
At each follow-up, the disappearance rate of SRF in the active treatment group seemed slightly better than in the control group, but no statistically significant differences were observed (P > 0.05 at each follow-up). The BCVA between the two groups also did not demonstrate statistically significant differences (P > 0.05 at each follow-up). Unlike the BCVA and the disappearance rate of SRF, we compared the change in central retinal sensitivity at 12 weeks after treatment; a statistical difference was observed (P = 0.042).
Our findings suggested that H. pylori eradication does not improve BCVA and the disappearance rate of SRF, but it could improve the central retinal sensitivity in acute ICSCR patients. We recommend that chronic ICSCR patients and more sensitive methods for H. pylori diagnosis should be involved in evaluating the effect of H. pylori eradication.
Therapeutics and Clinical Risk Management 09/2013; 9(1):355-60. DOI:10.2147/TCRM.S50407 · 1.47 Impact Factor
Available from: Patama Bhurayanontachai
- "Central serous chorioretinopathy (CSC) is an idiopathic condition characterized by the development of a well circumscribed, serous detachment of the neurosensory retina in the macula. This condition is common in healthy young adults between the ages of 20 and 50 years, especially in men with a type A personality,1 those under stress, or patients with elevated levels of corticosteroids from either corticosteroid administration or Cushing syndrome.2,3 Most patients are asymptomatic unless the central macula is affected. "
[Show abstract] [Hide abstract]
ABSTRACT: To evaluate photoreceptor disruption in patients with central serous chorioretinopathy (CSC) treated by half-dose photodynamic therapy (PDT).
A total of 29 patients with symptomatic CSC were recruited and underwent half-dose verteporfin PDT covering the leakage sites as observed via fundus fluorescein angiography. The primary outcome was the percentage of patients with the presence of photoreceptor disruption, and the secondary outcome was the correlation between photoreceptor disruption and visual results at the 1-year follow-up.
Photoreceptor disruption was identified in 13 eyes (44.8%) 12 months after treatment. Twenty-seven patients experienced best-corrected visual acuity (BCVA) improvement after PDT, while two patients showed stable BCVA. The mean BCVA in patients with photoreceptor disruption at the baseline and every follow-up visit was significantly lower than that of patients without photoreceptor disruption. However, there was no correlation between the presence or absence of photoreceptor disruption and the improvement of visual acuity because the BCVA gain at the last follow-up visit between the two groups was not significant (P = 0.69). No potential ocular complication was encountered in the study.
Photoreceptor disruption was found in about 45% of CSC patients treated by PDT, which ultimately resulted in poor visual outcomes. However, a half-dose PDT might not affect or modify the photoreceptor function because it gave the same pattern of visual recovery in patients with and without photoreceptor cell loss.
Clinical ophthalmology (Auckland, N.Z.) 01/2013; 7(1):87-92. DOI:10.2147/OPTH.S39584
Available from: europepmc.org
- "CSC is more common among patients with collagenosis, especially systemic lupus erythematosus (SLE) [7–9], accelerated hypertension [10,11] and hypercorticoidism . Other risk factors include antibiotic treatment , alcohol overdose , and corticosteroid therapy [11,13–16]. CSC after organ grafts  and within the period of pregnancy were also studied and described [18,19]. "
[Show abstract] [Hide abstract]
ABSTRACT: Central serous chorioretinopathy (CSC) is a condition that originates from alterations of the choroidal circulation. The aim of this paper was to evaluate the use of indocyanine green angiography (ICGA) in patients with chronic CSC.
The analysis included 17 patients (34 eyes) with chronic CSC in at least 1 eye. The eye examination included: distance and near visual acuity, biomicroscopy, applanation tonometry, fundus examination, colored and red-free fundus photography, evaluation of autofluorescence, optical coherence tomography, and fluorescein and indocyanine green angiography.
In 34 eyes (100%) involved in the ICGA study the results revealed zones of transient increased choroidal vessels permeability. In 18 eyes (52.9%) choroidal changes were accompanied by a focal serous pigment epithelial detachment. In 4 eyes (11.8%) of 3 patients' the ICGA examination confirmed the presence of occult choroidal neovascularization (CNV). In the patient with bilateral diffuse retinal pigment epitheliopathy, CNV was present in 1 eye, in the patient with unilateral chronic CSC it was also present in 1 eye, and in the third patient with bilateral chronic CSC it was detected in both eyes.
ICGA is a very useful examination that enables ophthalmologists to visualize choroidal changes due to chronic CSC, as well as to diagnose occult CNV in chronic CSC.
Medical science monitor: international medical journal of experimental and clinical research 02/2012; 18(2):CR51-57. DOI:10.12659/MSM.882455 · 1.43 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.